Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221500 · ClinicalTrials.gov registry record · Phase 2
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
A Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), sponsored by Nurix Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 18
- Study locations
NCT07221500: Recruiting Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), sponsored by Nurix Therapeutics.
NCT07221500 is a Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) that is actively recruiting participants, run by Nurix Therapeutics. The registered enrollment target is 100 participants, below the 188-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (47% lower). The trial reports 18 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07221500, a Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), is actively recruiting participants, sponsored by Nurix Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexobrutideg) works to treat patients with CLL/SLL. Participation could last up to 5 years, and possibly longer, if the disease does not progress.
Primary Outcome
The percentage of participants with response as determined according to 2018 International Workshop on CLL (iwCLL) guidelines. Response will include complete response (CR)/CR with incomplete marrow recovery (CRi), partial response (PR), and nodular PR.
Conditions Studied
Interventions
- DRUG NX-5948
Study Locations (18)
Other
- CHU de Nantes - Nantes
- AUSL della Romagna UO Ematologia - Ravenna
- Pratia Hematologia Sp. z o.o. - Katowice
- Pratia S.A. - Krakow
- Aidport Sp. z o.o. - Skorzewo
- Pratia Warszawa / Pratia MTZ - Warsaw
- The Royal Marsden NHS Foundation Trust - London
- The Christie NHS Foundation Trust - Manchester
Ohio
- University of Cincinnati - Cincinnati
- Oncology Hematology Care - Fairfield
Colorado
- Colorado Blood Institute - Denver
Florida
- Florida Cancer Specialists - Sarasota
Maryland
- Maryland Oncology Hematology - Silver Spring
North Carolina
- Novant Health Cancer Institute - Winston-Salem
Tennessee
- SCRI Oncology Partners - Nashville
Texas
- Texas Oncology - Center South - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-10-15 |
| Est. Completion | 2030-10 |
| Phase | Phase 2 |
What NCT07221500 shows while recruiting
NCT07221500 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 188-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (47% lower).
The record links to 2 conditions, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 1 intervention - of which NX-5948 is the first listed.
NCT07221500 lists 18 locations in 10 states (Other, Ohio, Colorado).
Frequently Asked Questions
What is clinical trial NCT07221500 about?
NCT07221500 is a clinical study titled "A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)". This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexo...
What is the current status of trial NCT07221500?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-10-15. Estimated completion is 2030-10.
What conditions does trial NCT07221500 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL).
What interventions are being tested in trial NCT07221500?
The interventions under investigation include: NX-5948 (DRUG).
Who is sponsoring clinical trial NCT07221500?
This trial is sponsored by Nurix Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07221500 being conducted?
This trial has 18 study locations across Colorado, Florida, Maryland, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia (CLL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07221500's enrollment target sits among peer trials
100 9th of 29 higher than 18 of 29 other Chronic Lymphocytic Leukemia (CLL) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia (CLL) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
RECRUITING · Phase 2
-
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
RECRUITING · Phase 2
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
ACTIVE NOT RECRUITING · Phase 2
-
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
ACTIVE NOT RECRUITING · Phase 2
-
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI